Discovery of AZD3199, an inhaled ultralong acting β2 receptor agonist with rapid onset of action

A series of dibasic des-hydroxy β2 receptor agonists has been prepared and evaluated for potential as inhaled ultra-long acting bronchodilators. Determination of activities at the human β-adrenoreceptors demonstrated a series of highly potent and selective β2 receptor agonists that were progressed...

Full description

Bibliographic Details
Main Authors: Stocks, Michael, Alcaraz, Lilian, Bailey, Andrew, Bonnert, Roger, Cadogan, Elaine, Christie, Jadeen, Dixon, John, Connolly, Stephen, Cook, Anthony, Fisher, Adrian, Flaherty, Alice, Humphries, Alexander, Ingall, Anthony, Jordan, Stephen, Lawson, Mandy, Mullen, Alex, Nicholls, David, Paine, Stuart, Pairaudeau, Garry, Young, Alan
Format: Article
Published: American Chemical Society 2014
Online Access:https://eprints.nottingham.ac.uk/2950/
_version_ 1848790915902078976
author Stocks, Michael
Alcaraz, Lilian
Bailey, Andrew
Bonnert, Roger
Cadogan, Elaine
Christie, Jadeen
Dixon, John
Connolly, Stephen
Cook, Anthony
Fisher, Adrian
Flaherty, Alice
Humphries, Alexander
Ingall, Anthony
Jordan, Stephen
Lawson, Mandy
Mullen, Alex
Nicholls, David
Paine, Stuart
Pairaudeau, Garry
Young, Alan
author_facet Stocks, Michael
Alcaraz, Lilian
Bailey, Andrew
Bonnert, Roger
Cadogan, Elaine
Christie, Jadeen
Dixon, John
Connolly, Stephen
Cook, Anthony
Fisher, Adrian
Flaherty, Alice
Humphries, Alexander
Ingall, Anthony
Jordan, Stephen
Lawson, Mandy
Mullen, Alex
Nicholls, David
Paine, Stuart
Pairaudeau, Garry
Young, Alan
author_sort Stocks, Michael
building Nottingham Research Data Repository
collection Online Access
description A series of dibasic des-hydroxy β2 receptor agonists has been prepared and evaluated for potential as inhaled ultra-long acting bronchodilators. Determination of activities at the human β-adrenoreceptors demonstrated a series of highly potent and selective β2 receptor agonists that were progressed to further study in a guinea pig histamine-induced bronchoconstriction model. Following further assessment by; onset studies in guinea pig tracheal rings and human bronchial rings contracted with methacholine (guinea pigs) or carbachol (humans), duration of action studies in guinea pigs after intratracheal (i. t.) administration and further selectivity and safety profiling AZD3199 was shown to have an excellent over all profile and was progressed into clinical evaluation as a new ultra-long acting inhaled β2 receptor agonist with rapid onset of action.
first_indexed 2025-11-14T18:20:12Z
format Article
id nottingham-2950
institution University of Nottingham Malaysia Campus
institution_category Local University
last_indexed 2025-11-14T18:20:12Z
publishDate 2014
publisher American Chemical Society
recordtype eprints
repository_type Digital Repository
spelling nottingham-29502020-05-04T16:43:16Z https://eprints.nottingham.ac.uk/2950/ Discovery of AZD3199, an inhaled ultralong acting β2 receptor agonist with rapid onset of action Stocks, Michael Alcaraz, Lilian Bailey, Andrew Bonnert, Roger Cadogan, Elaine Christie, Jadeen Dixon, John Connolly, Stephen Cook, Anthony Fisher, Adrian Flaherty, Alice Humphries, Alexander Ingall, Anthony Jordan, Stephen Lawson, Mandy Mullen, Alex Nicholls, David Paine, Stuart Pairaudeau, Garry Young, Alan A series of dibasic des-hydroxy β2 receptor agonists has been prepared and evaluated for potential as inhaled ultra-long acting bronchodilators. Determination of activities at the human β-adrenoreceptors demonstrated a series of highly potent and selective β2 receptor agonists that were progressed to further study in a guinea pig histamine-induced bronchoconstriction model. Following further assessment by; onset studies in guinea pig tracheal rings and human bronchial rings contracted with methacholine (guinea pigs) or carbachol (humans), duration of action studies in guinea pigs after intratracheal (i. t.) administration and further selectivity and safety profiling AZD3199 was shown to have an excellent over all profile and was progressed into clinical evaluation as a new ultra-long acting inhaled β2 receptor agonist with rapid onset of action. American Chemical Society 2014-02-08 Article PeerReviewed Stocks, Michael, Alcaraz, Lilian, Bailey, Andrew, Bonnert, Roger, Cadogan, Elaine, Christie, Jadeen, Dixon, John, Connolly, Stephen, Cook, Anthony, Fisher, Adrian, Flaherty, Alice, Humphries, Alexander, Ingall, Anthony, Jordan, Stephen, Lawson, Mandy, Mullen, Alex, Nicholls, David, Paine, Stuart, Pairaudeau, Garry and Young, Alan (2014) Discovery of AZD3199, an inhaled ultralong acting β2 receptor agonist with rapid onset of action. ACS Medicinal Chemistry Letters, 5 (4). pp. 416-421. ISSN 1948-5875 http://pubs.acs.org/journal/amclct doi:10.1021/ml4005232 doi:10.1021/ml4005232
spellingShingle Stocks, Michael
Alcaraz, Lilian
Bailey, Andrew
Bonnert, Roger
Cadogan, Elaine
Christie, Jadeen
Dixon, John
Connolly, Stephen
Cook, Anthony
Fisher, Adrian
Flaherty, Alice
Humphries, Alexander
Ingall, Anthony
Jordan, Stephen
Lawson, Mandy
Mullen, Alex
Nicholls, David
Paine, Stuart
Pairaudeau, Garry
Young, Alan
Discovery of AZD3199, an inhaled ultralong acting β2 receptor agonist with rapid onset of action
title Discovery of AZD3199, an inhaled ultralong acting β2 receptor agonist with rapid onset of action
title_full Discovery of AZD3199, an inhaled ultralong acting β2 receptor agonist with rapid onset of action
title_fullStr Discovery of AZD3199, an inhaled ultralong acting β2 receptor agonist with rapid onset of action
title_full_unstemmed Discovery of AZD3199, an inhaled ultralong acting β2 receptor agonist with rapid onset of action
title_short Discovery of AZD3199, an inhaled ultralong acting β2 receptor agonist with rapid onset of action
title_sort discovery of azd3199, an inhaled ultralong acting β2 receptor agonist with rapid onset of action
url https://eprints.nottingham.ac.uk/2950/
https://eprints.nottingham.ac.uk/2950/
https://eprints.nottingham.ac.uk/2950/